New Research on NeXtGen™ Biologics Inc.

An Executive Informational Overview (EIO) is now available on NeXtGen™ Biologics Inc., a closely held medical device company that holds a suite of patents for extracellular matrix (ECM) platform technology derived from the axolotl. The company aims to provide surgeons with advanced solutions for treating and managing a wide range of complex conditions in areas such as wound care, general surgery, trauma, plastic surgery, cardiovascular diseases, neurosurgery, orthopedics, and ophthalmology. The 48-page report details the Company's business, its strategy, market opportunities, competition, risks, and more. It is available for download below.

Snapshot

NeXtGen™ Biologics Inc. is a medical device company that possesses a collection of patents covering extracellular matrix (ECM) platform technology sourced from the axolotl, a rare paedomorphic salamander closely related to the tiger salamander. Leveraging the Company’s innovative biotechnology, NeXtGen is seeking to unravel the mysteries of regeneration and scar-free healing using the ECM of the axolotl, as this species is capable of regenerating organs and complex tissues (including its nervous system). The Company is currently developing platform solutions to address and enhance the treatment of various intricate conditions found in wound care, general surgery, trauma, plastic surgery, cardiovascular diseases, neurosurgery, orthopedics, and ophthalmology. NeXtGen’s first FDA-cleared device, NeoMatriX® Wound Matrix, is indicated for partial and full thickness wounds, pressure venous diabetic and chronic vascular ulcers, surgical wounds, trauma wounds, Mohs surgery, and burns. NeoMatriX is provided as sheets in various sizes for placement on wound beds to help manage the wound environment.

Key Points of NeXtGen™ Biologics Inc.

• The global medical device market for wound healing is expanding rapidly due to the increasing prevalence of chronic diseases (such as diabetes and obesity) and the surge in surgeries and injuries. Advanced wound care products, such as those which use ECM technology, are essential due to their effectiveness in promoting wound healing. 
  
  
• NeoMatriX uses a material from nature that has long been studied for its benefits of regeneration.
  
  
• NeXtGen owns a portfolio of trade secrets, including U.S and foreign issued and pending patent rights, for medical devices coatings, cosmetics, biologics, pharmaceuticals, and nutraceuticals.
  
  
• The Company is currently generating roughly $100,000/month.
  
  
• NeXtGen is led by an experienced team with proven success in pharmaceutical research, development, and commercialization.
  
  
• The Company has received $16.2 million of funding, including a $1.3 million SEED round (closed); $7.9 million raised through convertible notes (8% interest and 20% discount in “qualified equity financing”); and $6.4 million Common Stock (with $0.5 million remaining to reach convertible note). It currently seeks to raise an additional $5 million.
  
  
• The Company’s current cash position provides three months of runway with additional investment inflows expected to be imminent. 

*******************************************

Visit our Corporate Profile and Investment Highlights pages

for the latest research on NeXtGen™ Biologics Inc.

*******************************************